Chemomab Therapeutics Financials - Benzinga

SPY765.93+0.04%QQQ737.28+0.10%BTC/USD83,545.11−1.06%DIA514.30+0.05%GLD378.10+0.05%TLT78.66+0.05%

Chemomab Therapeutics Ltd

CMMBNASDAQ

Trade with Public

Trade with Public

$1.64

-0.52-24.07%

At close: Sep 28, 5:00 PM EST

$1.65

0.010.61%

After Hours: 6:57 PM EST

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Compare Stock Report

Chemomab Therapeutics Financials

Chemomab Therapeutics (CMMB) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
CORRECTION: Chemomab Therapeutics Q2 EPADS $(0.27) Misses $(0.15) Estimate

Chemomab Therapeutics (NASDAQ:CMMB) reported quarterly losses of $(0.27) per share which missed the analyst consensus estimate of $(0.15) by 80 percent. This is a 25 percent increase over losses of $(0.36) per share

Benzinga Newsdesk

PRO
Chemomab Therapeutics Q1 EPS $(0.24) Beats $(0.31) Estimate

Chemomab Therapeutics (NASDAQ:CMMB) reported quarterly losses of $(0.24) per share which beat the analyst consensus estimate of $(0.31) by 22.58 percent. This is a 57.14 percent increase over losses of $(0.56) per share

Benzinga Newsdesk

PRO
Chemomab Therapeutics Q4 EPS $(0.24) Beats $(0.40) Estimate

Chemomab Therapeutics (NASDAQ:CMMB) reported quarterly losses of $(0.24) per share which beat the analyst consensus estimate of $(0.40) by 40 percent. This is a 62.5 percent increase over losses of $(0.64) per share from

Benzinga Newsdesk

PRO
Chemomab Therapeutics Q3 EPS $(0.28) Beats $(0.40) Estimate

Chemomab Therapeutics (NASDAQ:CMMB) reported quarterly losses of $(0.28) per share which beat the analyst consensus estimate of $(0.40) by 30 percent. This is a 65 percent increase over losses of $(0.80) per share from

Benzinga Newsdesk

PRO
CORRECTION: Chemomab Therapeutics Q2 EPADS $(0.09) Misses $(0.07) Estimate

Chemomab Therapeutics (NASDAQ:CMMB) reported quarterly losses of $(0.09) per share which missed the analyst consensus estimate of $(0.07) by 20 percent. This is a 592.31 percent decrease over losses of $(0.01) per share

Benzinga Newsdesk

PRO
UPDATE: Chemomab Therapeutics Q1 EPADS $(0.14) Misses $(0.10) Estimate

Benzinga Newsdesk